FSG67
Based on 2 publication(s) in Google Scholar
FSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC50 of 24 μM.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.95%
- CAS. Nr.: 1158383-34-6
- Formel: C16H25NO4S
- Molecular Weight:327.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) FSG67
More-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
In Vivo Efficacy Study
-
IHC
Biologische Aktivität
GPAT[1]
FSG67 reduces GSK3β phosphorylation and signaling after acetaminophen overdose[1].
FSG67 results in a dose-dependent increase in oxidative metabolism in mature adipocytes with an IC50 of 27.7 ± 4.4 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1158383-34-6
-
Appearance Solid
-
Molecular Weight 327.44
-
Formel C16H25NO4S
-
Color Light yellow to yellow
-
SMILES
O=C(O)C1=CC=CC=C1NS(=O)(CCCCCCCCC)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. [Abstract]2024 Jun 1;14(9):3470-3485. PMID: 38948063
FSG67 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
FSG67 (30 μM; 24 h) decreased the MFI of Bodipy 558/568 C12 in MHCC97H SR and Hep3B SR cells.
FSG67 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
FSG67 (30 μM; 24 h) combined with sorafenib (MHCC97H SR: 10 μM; Hep3B SR: 6μM) decreased cell suvival.
FSG67 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
FSG67 (30 μM; 24 h) combined with sorafenib (MHCC97H SR: 10 μM; Hep3B SR: 6μM) induced cell apoptosis.
FSG67 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
FSG67 (1 mg/kg, once every 2 days for 7 injections; ip) combined with sorafenib (2 mg/kg, once every 3 days) decreased tumor growth in Four-week-old male B-NDG® mice (MHCC97H subcutaneous tumor-bearing model).
FSG67 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jun 1;14(9):3470-3485. [Abstract]
FSG67 (1 mg/kg, once every 2 days for 7 injections; ip) combined with sorafenib (2 mg/kg, once every 3 days) significantly reduced lipid content and NF-κB p65 expression in Four-week-old male B-NDG® mice (MHCC97H subcutaneous tumor-bearing model).
-
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (305.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.63 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Clemens MM, et al. The inhibitor of glycerol 3-phosphate acyltransferase FSG67 blunts liver regeneration after acetaminophen overdose by altering GSK3β and Wnt/β-catenin signaling. Food Chem Toxicol. 2019 Mar;125:279-288. [Content Brief]
[2]. Reilly SM, et al. Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3. Nat Metab. 2020 Jul;2(7):620-634. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0540 mL | 15.2700 mL | 30.5399 mL | 76.3499 mL |
| 5 mM | 0.6108 mL | 3.0540 mL | 6.1080 mL | 15.2700 mL | |
| 10 mM | 0.3054 mL | 1.5270 mL | 3.0540 mL | 7.6350 mL | |
| 15 mM | 0.2036 mL | 1.0180 mL | 2.0360 mL | 5.0900 mL | |
| 20 mM | 0.1527 mL | 0.7635 mL | 1.5270 mL | 3.8175 mL | |
| 25 mM | 0.1222 mL | 0.6108 mL | 1.2216 mL | 3.0540 mL | |
| 30 mM | 0.1018 mL | 0.5090 mL | 1.0180 mL | 2.5450 mL | |
| 40 mM | 0.0763 mL | 0.3817 mL | 0.7635 mL | 1.9087 mL | |
| 50 mM | 0.0611 mL | 0.3054 mL | 0.6108 mL | 1.5270 mL | |
| 60 mM | 0.0509 mL | 0.2545 mL | 0.5090 mL | 1.2725 mL | |
| 80 mM | 0.0382 mL | 0.1909 mL | 0.3817 mL | 0.9544 mL | |
| 100 mM | 0.0305 mL | 0.1527 mL | 0.3054 mL | 0.7635 mL |